机器人辅助部分肾切除术治疗大型血管平滑肌脂肪瘤的安全性与早期有效性
这项多中心系列研究纳入2005至2016年间美国五家学术中心的40例大型或有症状的血管平滑肌脂肪瘤(AML)患者,评估机器人辅助部分肾切除术(RAPN)的安全性与早期有效性。中位肿瘤直径7.2 cm,中位随访8个月,无患者出现AML相关症状,中位估算肾小球滤过率保留率为95%。作者认为RAPN似乎是大型AML安全的一线或二线(栓塞后)治疗,但需更长随访以充分评估疗效。
要点
- 40例大型或有症状AML患者接受RAPN,中位肿瘤直径7.2 cm,中位肾测量评分为9分。
- 围手术期输血4例(10%),术中并发症1例(2.5%),术后并发症7例次发生于6例患者(15%)。
- 中位随访8个月,无患者出现AML相关症状,中位eGFR保留率为95%。
核心结论
- 作者认为RAPN似乎是大型AML安全的一线或二线(SAE后)治疗,围手术期并发症谱良好且功能保留极佳。
- 作者指出需更长随访以充分评估治疗效果。
研究设计与样本
- 多中心系列研究,纳入2005至2016年间美国五家学术中心的40例大型或有症状AML患者,接受RAPN治疗。
- 记录并分析患者人口学特征、AML特征、手术与术后临床结局。
- 比较RAPN前接受选择性动脉栓塞(SAE)与未接受SAE患者的手术结局。
主要发现
- 中位(IQR)肿瘤直径为7.2(5-8.5)cm,中位(IQR)肾测量评分为9(7-10)。
- 6例(15%)有结节性硬化症病史,11例(28%)既往接受过SAE。
- 中位(IQR)手术时间和热缺血时间分别为207(180-231)分钟和22.5(16-28)分钟;8例(20%)采用非阻断技术。
- 中位(IQR)估计失血量为200(100-245)mL,4例(10%)术后接受输血;术中并发症1例(2.5%),术后并发症7例次发生于6例患者(15%)。
- 中位(IQR)随访8(1-15)个月,无患者出现AML相关症状;中位eGFR保留率为95%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需更长随访以充分评估治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate a multicentre series of robot-assisted partial nephrectomy (RAPN) performed for the treatment of large angiomyolipomas (AMLs). PATIENTS AND METHODS: Between 2005 and 2016, 40 patients with large or symptomatic AMLs underwent RAPN at five academic centres in the USA. Patient demographics, AML characteristics, operative and postoperative clinical outcomes were recorded and analysed. Surgical outcomes were compared between patients who underwent selective arterial embolisation (SAE) before RAPN and patients who did not undergo pre-RAPN SAE. RESULTS: The median (interquartile range [IQR]) tumour diameter was 7.2 (5-8.5) cm, and the median (IQR) nephrometry score was 9 (7-10). Six patients (15%) had a history of tuberous sclerosis and 11 (28%) had previously undergone SAE. The median (IQR) operative time and warm ischaemia time was 207 (180-231) and 22.5 (16-28) min, respectively. A non-clamping technique was used in eight (20%) patients. The median (IQR) estimated blood loss was 200 (100-245) mL, and four patients (10%) received blood transfusion postoperatively. One intraoperative complication occurred (2.5%), and seven postoperative complications occurred in six patients (15%). During a median (IQR) follow-up of 8 (1-15) months, none of the patients developed AML-related symptoms. The median estimated glomerular filtration rate preservation rate was 95%. There were no differences in operative or perioperative outcomes between patients who underwent SAE before RAPN and those who did not. CONCLUSIONS: Robot-assisted partial nephrectomy appears to be a safe primary or secondary (post-SAE) treatment for large AMLs, with a favourable perioperative morbidity profile and excellent functional preservation. Longer follow-up is required to fully evaluate therapeutic efficacy.
引用
- Golan S, Johnson SC, Maurice MJ, et al. Safety and early effectiveness of robot-assisted partial nephrectomy for large angiomyolipomas. BJU Int. 2017. PMID: 27988984. doi:10.1111/bju.13747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。